Lambert-Eaton Myasthenic Syndrome; Pathogenesis, Diagnosis, and Therapy
Autoimmune Diseases · 2011 · 2011 · 1-5
DOI: 10.4061/2011/973808 ↗Kurz gefasst
Fachartikel in der Zeitschrift Autoimmune Diseases, 2011. Verfasst von Nils Erik Gilhus. Beteiligte Einrichtung: Department of Clinical Medicine, University of Bergen, 5020 Bergen, Norway. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
Lambert-Eaton Myasthenic Syndrome (LEMS) is a rare disease with a well-characterized pathogenesis. In 50% of the patients, LEMS is a paraneoplastic manifestation and caused by a small cell lung carcinoma (SCLC). Both LEMS patients with SCLC and those without this tumour have in 85% of cases pathogenetic antibodies of very high LEMS specificity against voltage-gated calcium channels (VGCCs) in the cell membrane of the presynaptic motor nerve terminal. Better understanding of LEMS pathogenesis has lead to targeted symptomatic therapy aimed at the neuromuscular junction and to semispecific immuno-suppression. For SCLC LEMS, tumour therapy is essential.
Autor:innen und Institutionen
- Department of Clinical Medicine, University of Bergen, 5020 Bergen, Norway.
Zitieren
APA
Gilhus, N. E. (2011). Lambert-Eaton Myasthenic Syndrome; Pathogenesis, Diagnosis, and Therapy. Autoimmune Diseases, 2011, 1-5. https://doi.org/10.4061/2011/973808
Vancouver
Gilhus NE. Lambert-Eaton Myasthenic Syndrome; Pathogenesis, Diagnosis, and Therapy. Autoimmune Diseases. 2011;2011:1-5. doi:10.4061/2011/973808
BibTeX
@article{Gilhus2011,
author = {Gilhus, Nils Erik},
title = {Lambert-Eaton Myasthenic Syndrome; Pathogenesis, Diagnosis, and Therapy},
journal = {Autoimmune Diseases},
year = {2011},
volume = {2011},
pages = {1--5},
doi = {10.4061/2011/973808}
}
EUVIMED